NCT01337180

Brief Summary

Exposure to noxious gases and particles is associated with an increased prevalence of respiratory and cardiovascular diseases. Thus, investigation of possible airway inflammation and/or systemic inflammation in workers exposed to high levels of dust is important. Silicon Carbide (SiC) Processing Inc. provides cutting fluid (slurry) for the production of solar cells and is at present the largest provider of slurry to the solar industry worldwide. In the production process, the recyclable materials (SiC), polyethylene glycol (PEG)) of the used slurry are recovered. The airborne exposure consists mainly of SiC (dust particles) and evaporation from the recycling of PEG. High levels of dust have been measured and, seventeen per cent of the measurements in the processing hall were equal to or higher than the Norwegian occupational exposure limit. Thus, assessment of possible systemic and airway effects of this exposure is of interest. A prospective design will be applied and the effects studied by means of registration of respiratory symptoms, spirometry, nitric oxide (NO) in exhaled air, induced sputum and blood sampling over a 3 year period. Exposed subjects will also be compare with non- or low exposed subjects (administrative/office workers). Efforts will be made to include all eligible subjects and to avoid drop-outs. If early signs of airway or systemic inflammation in workers or in cells are demonstrated in the study, it will be necessary to implement measures to reduce the exposure levels. The primary aim of the present study of workers exposed to Silicon Carbide dust in the workplace is to determine whether this exposure is associated with inflammatory changes in the lungs. The secondary aims are: - to examine possible changes in systemic inflammatory markers and - to examine changes in lung function among Silicon Carbide processing workers during a period of 3 years. Possible changes in lung function will be monitored by spirometry and gas diffusion measurements (study A). Airway inflammatory responses and changes in circulating inflammatory markers will be assessed by examination of the induced sputum samples and blood samples every 6th month in a subgroup of workers (study B).

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Mar 2011

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2011

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

April 15, 2011

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 18, 2011

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2014

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2014

Completed
Last Updated

November 20, 2015

Status Verified

June 1, 2013

Enrollment Period

2.9 years

First QC Date

April 15, 2011

Last Update Submit

November 19, 2015

Conditions

Keywords

lung functionrespiratory symptomsdustinflammationprospective

Study Arms (1)

Main study group

Inclusion criteria: Employment at one of the plants (SiC I) and (SiC II) in Porsgrunn. Both administrative/office workers and workers in the production and maintenance departments will be invited to participate. Non-smokers and smokers and male and female workers will be included in the main study group (study A). Sputum part of study: nonsmokers.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Employment at one of the plants (SiC I) and (SiC II) in Porsgrunn. Both administrative/office workers in the production and maintenance departments will be invited to participate. Non- smokers and smokers and male and female workers will be included in the main study group. Only non- smokers will be included in the sputum part of the study.

You may qualify if:

  • Employment at SiC plant in Porsgrunn;

You may not qualify if:

  • smoking
  • active airway infection or less then 3 weeks after recovery
  • active allergy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sykehuset Telemark

Skien, Telemark, 3710, Norway

Location

Related Publications (12)

  • Sioutas C, Delfino RJ, Singh M. Exposure assessment for atmospheric ultrafine particles (UFPs) and implications in epidemiologic research. Environ Health Perspect. 2005 Aug;113(8):947-55. doi: 10.1289/ehp.7939.

    PMID: 16079062BACKGROUND
  • Bruch J, Rehn B, Song H, Gono E, Malkusch W. Toxicological investigations on silicon carbide. 1. Inhalation studies. Br J Ind Med. 1993 Sep;50(9):797-806. doi: 10.1136/oem.50.9.797.

    PMID: 8398873BACKGROUND
  • Bruch J, Rehn B, Song W, Gono E, Malkusch W. Toxicological investigations on silicon carbide. 2. In vitro cell tests and long term injection tests. Br J Ind Med. 1993 Sep;50(9):807-13. doi: 10.1136/oem.50.9.807.

    PMID: 8398874BACKGROUND
  • Allen M, Butter R, Chandra L, Lettington A, Rushton N. Toxicity of particulate silicon carbide for macrophages, fibroblasts and osteoblast-like cells in vitro. Biomed Mater Eng. 1995;5(3):151-9.

    PMID: 8555965BACKGROUND
  • Fell AK, Sikkeland LI, Svendsen MV, Kongerud J. Airway inflammation in cement production workers. Occup Environ Med. 2010 Jun;67(6):395-400. doi: 10.1136/oem.2009.047852. Epub 2009 Oct 22.

    PMID: 19854695BACKGROUND
  • Toren K, Brisman J, Jarvholm B. Asthma and asthma-like symptoms in adults assessed by questionnaires. A literature review. Chest. 1993 Aug;104(2):600-8. doi: 10.1378/chest.104.2.600.

    PMID: 7802735BACKGROUND
  • Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005 Aug;26(2):319-38. doi: 10.1183/09031936.05.00034805. No abstract available.

    PMID: 16055882BACKGROUND
  • Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005 Oct;26(4):720-35. doi: 10.1183/09031936.05.00034905. No abstract available.

    PMID: 16204605BACKGROUND
  • Sikkeland LI, Haug T, Stangeland AM, Flatberg G, Sostrand P, Halvorsen B, Kongerud J. Airway inflammation in paper mill workers. J Occup Environ Med. 2007 Oct;49(10):1135-42. doi: 10.1097/JOM.0b013e31814b2e87.

    PMID: 18000418BACKGROUND
  • Pin I, Gibson PG, Kolendowicz R, Girgis-Gabardo A, Denburg JA, Hargreave FE, Dolovich J. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax. 1992 Jan;47(1):25-9. doi: 10.1136/thx.47.1.25.

    PMID: 1539140BACKGROUND
  • Sikkeland LI, Kongerud J, Stangeland AM, Haug T, Alexis NE. Macrophage enrichment from induced sputum. Thorax. 2007 Jun;62(6):558-9. doi: 10.1136/thx.2006.073544. No abstract available.

    PMID: 17536036BACKGROUND
  • American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005 Apr 15;171(8):912-30. doi: 10.1164/rccm.200406-710ST. No abstract available.

    PMID: 15817806BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Induced sputum, serum, citrate- plasma, EDTA-plasma, whole blood and a PaxGene sample for DNA isolation. Cell isolation, RNA isolation and gene expression analysis. Fluid phase analyses.

MeSH Terms

Conditions

Lung Diseases, ObstructiveInflammationSigns and Symptoms, Respiratory

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsSigns and Symptoms

Study Officials

  • Johny Kongerud, professor

    Oslo University; Oslo University Hospital

    STUDY DIRECTOR
  • Berit Bakke, PhD

    National Institute of Occupational Health

    PRINCIPAL INVESTIGATOR
  • Anne Kristin M Fell, MD

    Sykehuset Telemark

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Consultant

Study Record Dates

First Submitted

April 15, 2011

First Posted

April 18, 2011

Study Start

March 1, 2011

Primary Completion

February 1, 2014

Study Completion

December 1, 2014

Last Updated

November 20, 2015

Record last verified: 2013-06

Locations